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As HIV replicates, mutations in the HIV
genome develop due to errors in the transcrip-
tion of RNA to DNA by the viral enzyme
reverse transcriptase. When these errors are
introduced into viral genes, a mutation may
result.  If the mutation occurs in one of the HIV
proteins that is a target of an antiretroviral
drug, the result may be decreased susceptibil-
ity or resistance to that drug, and lack of inhi-
bition of viral replication by that drug. All prog-
eny virions that are produced from a cell har-
boring mutant, resistant virus contain the same
mutation or set of mutations. Approximately
one mutation is introduced into the virus
genome with each cycle of virus replication.1
Because HIV replicates at such a rapid rate -
roughly one to 10 billion viral particles are pro-
duced daily2 - virtually all possible mutations in
the HIV genome are generated within a patient
on a daily basis.  In this way, all HIV patients,
including those naïve to therapy, harbor a
diverse population of viruses with differing sus-
ceptibilities to the currently available antiretro-
viral drugs.  When a patient starts antiretroviral
therapy, failure to achieve or maintain plasma
viral loads below quantifiable levels invariably
leads to the selection of virus that contains
mutation(s) that confer a survival advantage to
the virus; in this case, there is some degree of
resistance to one or more drugs within the
patient's combination. Virus that is resistant to
a drug within one class of antiretroviral agents
is often cross-resistant to other drugs within
the same class. Thus, when patients develop
resistant virus, the potential to construct effec-
tive combinations of antiretroviral medications
declines quickly. In order to achieve the goal of
inhibiting virus replication and maintaining
immunologic function in individuals who will
live with HIV infection for decades, the selec-
tion of combinations that limit resistance and
maintain therapeutic options for those who fail
is essential.
Assays are now available that allow for the
identification of resistant virus. The value of
resistance assays has been validated by (1)
improved outcomes in randomized clinical tri-
als in which treatment decisions are made with
resistance data compared to those made with-
out this information and (2) from clinical trials
that demonstrate improved virologic outcomes
when patients receive more agents to which
their virus is sensitive as determined by resis-
tance tests.3-5
Types of Resistance Assays
Assays that report HIV resistance do so in two
ways. Phenotypic resistance tests measure
the concentration of drug needed to inhibit the
eplication of a patient's virus. Typically, this is
quantitated by specifying the concentration of
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drug needed to inhibit 50% or 90% of virus
replication (IC50 or IC90), or by compar-
ing the fold-change in drug concentration
required to inhibit the replication of the
patient's virus compared to a representa-
tive, wild type, sensitive virus isolate.
Genotypic resistance tests report the
presence of specific mutations in the
amino acid sequences of the HIV genome
that encode the reverse transcriptase or
protease enzymes, the targets of the HIV
reverse transcriptase and protease
inhibitors, or the part of the HIV genome
that encodes a specific region that is the
target of the HIV entry inhibitor.
Interpretation of Resistance Tests
For phenotypic tests in order to know
whether a drug is potentially active
against a virus, one must compare the
IC50 or fold-change in virus susceptibility
to a particular drug to the "clinical cut-off"
of that drug.  The clinical cut-off refers to
the fold-change of virus susceptibility
above which the drug has less activity in
vivo.  Often there are two cut-offs.  Virus
with a fold-change in susceptibility below
the lower cut-off is fully susceptible, while
virus with a fold-change in susceptibility
above the higher cut-off is very unlikely to
be inhibited at all. Virus with a fold-change
between the cut-offs is partially suscepti-
ble. One of the limitations of the use of
phenotypic resistance tests is that clinical
cut-offs have not been clearly established
for some of the nucleotide reverse tran-
scriptase inhibitors or protease inhibitors
used alone or boosted with ritonavir.
Genotypic resistance tests report the
codon(s) in the amino acid sequence of
the virus that differs from wild type. Only
those mutations with known impact on
virus susceptibility are typically listed.
With each mutation reported three pieces
of information are usually given: the num-
ber of the codon in the amino acid
sequence that is mutated, the wild-type
base, and the mutant base. Genotypic
resistance tests provide an interpretation
that assesses the impact of the particular
set of mutations observed in the patient's
virus on the susceptibility of that virus to
available drugs. This interpretation is
derived in one of two ways.  One method
is the application of an algorithm based
upon a set of rules that link specific muta-
tions with known patterns of resistance to
a drug.  The algorithms used for interpre-
tation need to be regularly updated in
order to include newly described muta-
tions associated with resistance.  Rules-
based algorithms often fail to consider the
interaction that several mutations may
have on virus susceptibility.  The second
method for interpretation of genotypic
resistance is the VirtualPhenotypeTM
(Virco).  In this system, the sequence of
the patient's virus is matched with viruses
that have similar genotypes stored in a
database. The viruses represented in the
database have had phenotypic virus sus-
ceptibilities performed.  The virtual pheno-
type provides the average fold-change in
IC50 of these viruses, gives the approxi-
mate proportions of matched viruses in
the database that are fully or partially sus-
ceptible or resistant, and indicates
whether the patient's virus is more likely to
be sensitive or resistant. The virtual phe-
notype does not report whether the
patient's virus is sensitive or resistance; it
provides an estimate of the probability
that the virus is sensitive or resistant.   
Limitations of Resistance Testing and
Discordance Between Phenotypic and
Genotypic Resistance Test Results
There are certain limitations to the use of
resistance tests. Because the current
phenotypic and genotypic resistance test
methodologies require PCR amplification
of segments of the HIV genome, these
assays may not be successfully per-
formed when the patient's viral load is low.
Generally, the viral load needs to be
above 500 to 1,000 copies HIV-1 RNA/mL
to obtain a result.  In addition, resistance
tests should be obtained with the patient
continuing on therapy.  Resistant virus in
patients who stop therapy may decline in
concentration as it is out-competed by
wild type virus that is warehoused within
latently infected cells.6 The resistant virus
will re-emerge if the selective pressure of
therapy is resumed. Therefore, if patients
have been off therapy for one or more
months, it may be best to resume therapy
for a period of time prior to obtaining a
resistance test.  Resistance tests results
are, most reliably, a reflection of the pat-
tern of resistance to the drugs the patient
is currently taking. Mutations present at
one time point may not be detected at a
second time point after a patient has
switched therapy. Mutant virus on one
combination that is lost following a change
in therapy will reemerge if the patient
cycles back to drugs that were used pre-
viously.  For these reasons, when consid-
ering modification of an antiretroviral com-
bination, resistance tests are a better indi-
ation of what drugs will not be effective,
rather than an indication of what drugs will
be effective. In addition, knowledge of
prior patterns of resistance may be of
value when selecting a new combination
with the knowledge of a recent resistant
test result.
Indications for Use of Resistance Tests
The International AIDS Society (IAS) -
USA and the Panel on Clinical Practices
for Treatment of HIV Infection of the U.S.
Department of Health and Human
Services (DHHS) have published recom-
mendations on the use of resistance
tests.7,8 Both expert panels recommend
resistance testing in patients with acute
HIV infection or recent HIV infection,
defined as seroconversion within the past
one to two years.  This recommendation is
based upon a study that identified a
cohort of patients with acute HIV infection,
and demonstrated that of those who were
infected in 1999 and 2000, 14% were
infected with drug resistance virus.9 In
addition, drug resistance can be quite sta-
ble in this group of acutely infected indi-
viduals, with resistance to all classes of
agents persisting for over a year in some
patients.10 The guidelines differ with
respect to recommending resistance test-
ing prior to initiating therapy in patients
with chronic infection of more than two
years duration - the IAS panel recom-
mends testing, while the DHHS panel rec-
ommends considering it.  A recent report
in 10 major U.S. cities demonstrated that
patients with chronic HIV infection were
just as likely to harbor resistant virus as
those with acute infection.11 Resistance to
the nucleoside reverse transcriptase
inhibitors was most common.  Therefore,
resistance testing in antiretroviral naïve
patients is increasingly common, irrespec-
tive of the duration of infection.
Resistance testing is recommended in
pregnant women with quantifiable viral
loads in order to optimize therapy and
minimize the risk of vertical transmission.
Resistance testing is recommended in all
patients with virologic failure prior to
beginning a new antiretroviral combina-
tion.  Patients with a quantifiable viral load
on their initial combination may have virus
that is resistant to only one, or perhaps
two, agents in their combination. These
individuals have many options for their
ext combination, and their therapy
should ideally be switched to three new
drugs, even if they exhibit virus that is only
resistant to a single agent.  In patients
who fail multiple regimens, the pattern of
resistance is typically complex.
Resistance testing is used to optimize the
therapeutic response, but the goal of
achieving an undetectable viral load may
not be possible. In addition, if a patient's
CD4+ lymphocyte count is high, it may be
prudent to withhold an agent or class of
2
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Resistance testing is rec-
ommended in all patients
with virologic failure prior to
beginning a new 
antiretroviral combination.
3agents if it is unlikely that the patient will achieve an undetectable
viral load, in the hopes that when newer agents are available a
combination can be constructed that will be more successful in
reducing the viral load below detectable levels.
Selecting Genotypic or Phenotypic Resistance Testing
Phenotypic resistance testing is more costly than genotypic test-
ing. Therefore, genotyping may be preferred in resource limited
settings.  However, in true resource limited areas, neither of these
may be an option.  Despite the high cost of this monitoring, the
selection of the most effective combination, and the prevention of
additional virologic failure, virus resistance, and CD4+ count
decline will be the most cost effective strategy in the long run, as
it better achieves the most effective combination of drugs and lim-
its or delays treatment failure.  A genotypic resistance test is usu-
ally adequate when testing a treatment naïve patient prior to initi-
ating therapy or evaluating a patient failing on their first combina-
tion. However, the more complex the mutational pattern, the
greater the value of a phenotypic resistance test. Patients who
have failed more than three combinations will often harbor multi-
ple mutations, and both a genotypic and phenotypic resistance
test may be necessary to optimize the next combination.
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This year the Infectious Diseases Society of America (IDSA) host-
ed a seminar at which Drs. Godofsky, Sulkowski, Dieterich, and
McGovern all gave lectures pertaining to coinfection and monoin-
fection with hepatitis C virus (HCV) and HIV.  Below are the high-
lights from this seminar.
HCV affects an estimated four million persons in the United States
with a prevalence of approximately 1.8% in the general public.
The prevalence of HCV for those incarcerated is much higher. The
number of inmates with HCV is approximately 255,000, giving a
prevalence of 15%.  This risk is not contained within correctional
facilities, since those released can transmit HCV to their home
communities when they return. 
In recent years, the incidence of acute HCV infection in the U.S.
has declined, in part to mandatory blood supply screening.  The
most significant risk factors for HCV transmission include injection
drug use, accounting for approximately 60-70% of all new cases of
HCV, and sexual transmission, accounting for up to 20% of new
cases. The limited number of clinicians treating HCV, approxi-
mately 2,200, and limited resources, including time, staff, and edu-
cation, are inadequate in meeting the needs of the large number
of patients who are infected with HCV or with both HCV and HIV.  
While HCV and HIV have similar modes of transmission, the effi-
ciency of transmission of each virus is very different. The HCV
virus is transmitted primarily through blood, with injection drug use
being the leading route of transmission. The leading route of trans-
mission for HIV is unprotected heterosexual contact. Based on the
different modes of transmission, both demographic and clinical dif-
ferences in the HIV/HCV-coinfected and HIV-monoinfected patient
can be seen.  In outpatient studies, coinfected persons have been
found to be more likely to have used injection drugs, to be older, to
be nonwhite, to have received less than 12 years of education, and
to have undergone care with use of public funds.  HIV exacerbates
the natural history of HCV; among those infected with HCV, those
with concurrent HIV infection are less likely to have cleared infec-
tion with HCV than those without HIV infection.  HIV infection has
also been associated with higher HCV RNA viral load and a more
rapid progression of HCV-related liver disease. Accordingly, guide-
lines have been developed for the management of HCV in HIV-
i fected persons. These guidelines recommend initial treatment of
HCV in HIV-infected persons with pegylated interferon plus rib-
avirin for 48 weeks.  Additionally, HIV/HCV-coinfected persons on
HCV treatment should be monitored closely given the high likeli-
hood of adverse effects.
The AIDS Pegasys Ribavirin International Co-Infection Trial
(APRICOT) evaluated the efficacy and safety of pegylated inter-
feron alfa-2a plus ribavirin (PEG IFN alfa-2a plus RBV) in 868
HIV/HCV coinfected patients.  Patients were randomized to one of
three 48-week regimens.  The overall sustained virologic response
(SVR) of 40% was the highest in the regimen including PEG IFN
alfa-2a plus RBV, compared to an SVR of 12% and 20%, for regi-
mens excluding ribavirin.
Drug-associated hepatotoxicity has emerged as a major issue in
th  era of highly active antiretroviral therapy (HAART).  In patients
infected with HIV, hepatotoxicity can lead to liver-related morbidity,
iscontinuation of treatment, and death.  Drug reactions are clas-
sified into two categories: predictable drug reactions, which are
often dose-dependent, and unpredictable drug reactions, which
are host-dependent and not dose-dependent. Unpredictable drug
reactions occur when a drug is converted into a metabolite that is
either toxic or acts to provoke some hypersensitivity reaction.
Furthermore, unpredictable drug reactions are further classified
into immunologic idiosyncratic reactions, such as hypersensitivity
reactions accompanied by fever and rash, which occur with a short
latency of onset, and idiosyncratic metabolic reactions, character-
ized by a long latency before onset.  Patient vulnerability to liver
injury is dependent on the toxification/detoxification processes
involved in drug metabolism.  Up-regulation of cytochrome P450
(CYP 450) can increase production of certain toxic metabolites.
Factors contributing to increased susceptibility to drug-inducted
liver disease include age, gender, HIV infection, and alcohol use. 
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Dear Correctional Colleagues:
Beginning with the uprising at the Stonewall bar in New York City in 1969, a new sense of freedom
and pride reverberated across this country among gay men and women. Twenty-five years ago,
the first cases of a strange "gay plague" were recognized in this country. In major city cent rs
across the U.S., young gay men were diagnosed with mysterious illnesses that had previously only
been seen in those with severe immunodeficiency due to cancer or chemotherapy. By the early
eighties, much of the enthusiasm of the seventies gave way to fear, ignorance, and ostracism
directed towards the lifestyle of those infected. Precious years were lost, during which education
and prevention efforts might have changed the course of the epidemic. Worldwide, millions have
died, tens of millions of children have been orphaned, and over 40 million people have been infect-
ed with HIV.   
Thankfully, this past decade has brought hope to some of those who are living with HIV.
Antiretroviral therapy continues to evolve, and many of those who are HIV-infected now have a
chance to live longer more productive lives. Woefully, however, the benefits have been limited to a
relatively small group of individuals in wealthier countries. Most of those who are HIV-infected
around the world are not even aware of their infection, and most of those who are infected have
no realistic hope of ever acquiring life-extending treatments. And, perhaps because of the failure
to respond more forcibly in the early years of this epidemic, the virus has now made dramatic
inroads to all sectors of humanity… men, women, children, gays and straights, injection drug users,
hemophiliacs, and others.  
As we commemorate World AIDS Day on December first this year, let us pause to remember all of
those who have suffered through the years as a result of this virus. Let us especially remember the
women- our mothers, sisters, aunts, wives, daughters, and lovers. Women not only have the high-
est incidence of new infections, but because of their role as caregivers and nurturers are dispro-
portionately affected by HIV as well. Let us continue to speak out for society's marginalized HIV-
infected persons… prisoners, injection drug users, commercial sex workers, the poor, and others.
As Martin Luther King once said, "our lives begin to end the moment that we stop speaking out
about things that matter".
This month, IDCR features a review of HIV resistance testing by Dr. Ian Frank, and we reprint
tables from the Stanford database on resistance mutations. California DOC inmate Michael
Simmons offers an insider's view on inmate peer education programs, we offer highlights from
recent conferences, and we announce the selection of Dianne Rechtine as the first recipient of the
Stephen Tabet Award for Excellence in correctional healthcare. Next month, we will bring you an
update on changes in HIV treatment guidelines. Thank you for your continued readership, and we
welcome your suggestions for future topics.
Sincerely,
Joseph Bick, MD
LETTER FROM THE EDITOR
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High Level Resistance
Intermediate Resistance
Low Level Resistance
Contributes to Resistance
No Resistance
Hypersensitivity
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NFV   SQV   IDV   RTV   APV  LPV   ATV
AZT   D4T   TDF   ABC   DDI   3TC   FTC
30
48
50V
82
84
90
46
47
53
54
24
32
73
88
10
20
33
36
63
71
77
41
67
70
210
215
219
184
69
65
74
75TM
62
751
77
116
151
69SS
44
118
115
HIV DRUG RESISTANCE
NVP   DLV   EFV
98G
98S
100I
101E
101P
103NS
103R
106A
106M
106I
108I
179D
179I
181CIV
188L
188C
188H
190A
190S
190EQ
225H
227L
230L
Taken from the Stanford HIV Drug Resistance Database
for more information visit http://hivdb.stanford.edu
Tables last updated October 25, 2004
6INMATE PEER EDUCATION PROGRAMS: 101
By Thomas Michael Simmons*, incarcerated at California State Prison, Lancaster, where he serves as an Inmate Educator of the Inmate Peer
Education Program
Prison populations have swollen to juggernaut proportions in
recent years.  Each institution is not only a microcosm of disparate
cultures, ethnicities, and lifestyles compressed into a seething
mass of apathy, despair, distrust and uncertainty - but also a petri
dish fermenting transmission of any number of communicable dis-
eases.
Unconfined to prison walls, infections may be carried back to soci-
ety itself upon a prisoner's release, or even by staff and visitor
contact with the infected. This brings serious challenges to prison
administrators and health care providers alike, especially in times
of constrained budgets.  However, opportunities do exist for inter-
vention.
In 1996, the Joint United Nations Program
on HIV/AIDS (UNAIDS) emphasized the
importance of health care/disease preven-
tion by stating, "Prisoners are the commu-
nity. They come from the community, they
return to it. Protection of prisoners is pro-
tection of our communities."1
In the late 1980s, the California
Department of Corrections' Health Care
Services Division (HCSD) created the
Inmate Peer Education Program (IPEP.)
While similar programs now exist else-
where (Florida, Louisiana, Texas, etc), all
share a unique commonality in challenging
the long-held stereotype of "convict men-
tality", and bring about an opportunity for
positive change in the attitudes and behaviors of others. Peer
educators are able to "speak the language" of other inmates, and
may share similar experiences - thus having a more inherent
credibility than those who represent "the system" (often distrusted
or even ignored). Peer educators can be quite successful in win-
ning the trust of the inmate population. Inmate educators also
develop a positive focus and purpose in their lives, empowered by
the perception of their ability to influence others in ways never
believed possible - thus improving self-esteem, knowledge, and
renewed commitment to the community.
Peer education programs focus on developing student attitudes
and feelings, encouraging honesty, cooperation, and independent
learning. Such programs emphasize mutual respect, discussion,
and reinforcement of positive behavior.  Peer programs provide a
more humanistic approach, recognizing that learning is a change
that develops in oneself that results from experiences.  Through
their efforts and behaviors, peer educators promote change in the
prison culture and some of the socially accepted "norms" as a
result. Through this commitment, peer educators can be deeply
affected. As they see the change they bring about in others
through fairness and balance in their presentations, inter-group
relations overcome racism, sexism, and culturalism.  Stereotypes
are replaced by a more positive socialization; differences in oth-
ers are acknowledged and embraced.
Developed and audited by the HCSD, Field Operations, Office of
Continuing Education and Training, the IPEP is designed to serve
the prison population throughout the state.  Inmate educators are
trained to provide current, medically correct health information to
raise awareness regarding infectious diseases (HIV, hepatitis,
STDs, TB, Staph), as well as other health-related subjects that
plague the prison system, and society at large.  Daily operations
and supervision are delegated through each institution's chain of
command to the staff member designated as the Institutional Peer
Education Coordinator.
Those selected to become peer educators
have a tremendous responsibility - not only do
their peers expect them to be knowledgeable
and current on recent developments in infec-
tious disease, but staff and inmates alike
expect them to be positive role models.
Inmate educators are held, and hold each
other, to a high standard of conduct.  A
screening and training process is employed,
and subsequent to certification, all agree to
adhere to a set of standards and expectations
- failure of which are grounds for removal from
the program.  Such a process is used to avoid
participation of those who may have their own
"personal agendas" that are adverse to the
mission of the program.
Candidates are recruited by either referral or
through postings in the housing units. The
applicant's central file is reviewed to see if there are case factors
that would impede his/her credibility and effectiveness, or pose a
threat to security.  Applicants are interviewed by the IPEP
Coordinator, who then determines their suitability for training. A
rigorous training program ensues, after which the candidate gives
presentations that are evaluated by the group and coordinator.
Upon successful completion, certification is issued.  Work does
not stop here, however, as all Peer Educators must participate in
regular training sessions and Continuing Medical Education, and
conduct a minimum of one presentation per quarter to maintain
certification. Educators offer a variety of services including formal
classes, informal groups/support groups, and personal counsel-
ing, in order to combat the enormous amount of ignorance and
misinformation that exists within and outside the prison.
Misconceptions that have bred fear, prejudices, and stigmatiza-
tion are countered by the vital exchange of information which
improves the general public's health and safety, as inmates often
relay information to relatives and friends, either at visits, by mail,
or telephone.  Educators have also shared current information on
disease management with medical staff unaware of recent devel-
opments.
Program success is a collaborative effort between peer educa-
tors, the HCSD, administrators and custodial staff that wholly
Continued on page 7
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Peer education programs
focus on developing 
student attitudes 
and feelings,
encouraging honesty,
cooperation, and 
independent learning.
7depends on involvement and support which are vital in enabling
access to housing units, classrooms, and work sites. Equally
important is support given by individuals and community-based
organizations (CBOs), where training and resources are
acquired or shared. Prison administrators are realizing that peer-
based programs have four key advantages: credibility, range of
services, benefits to inmates and peer educators, and cost-
effectiveness.
Problems that beset the program are the occasional obstacles
raised by lockdowns, correctional staff who are either unaware
of the program's efficacy, or unwilling to accept the idea that
inmates can take on personal responsibility for themselves and
others.  Yet, as the program grows, such obstacles are removed.
Another problem that arises is the availability of accurate and
current information. Inmates in maximum-security institutions
cannot directly access websites created by various health agen-
cies/organizations. They must depend on the kind support of
agencies like the CDC, NIH, Immunization Action Coalition,
American Foundation for AIDS Research, IDCR, AIDS Project:
Los Angeles, Immunization Action Coalition, UNAIDS, and a
host of others to obtain such invaluable educational tools freely.
Here at the California State Prison in Lancaster, the IPEP has
continued to receive the excellent support of the warden, asso-
ciate wardens and custody staff in enabling its mission to con-
tinue.
Peer education continues to remain an effective means of
addressing HIV/AIDS, hepatitis, STDs, and TB cases within the
prison system(s), as well as target populations in the public sec-
tor. One often gets lost in the eddies of mass campaigns that
exist to address the various epidemics, unable to see clearly
how it takes each individual person's efforts to create changes in
people's lives, and eventually changes that would bring such
epidemics under control.  Even the smallest, seemingly insignif-
icant person can change their world, their future, and that of the
world around them. Peer education proves that.
DISCLOSURES:
*Nothing to Disclose
REFERENCES: 
1. "HIV/AIDS in Prisons."  UNAIDS, 1996.
The 2004 annual Conference of the National Commission on
Correctional Health Care took place on November 13-17 2004 in
New Orleans, Louisiana. This meeting is one of the most impor-
tant gatherings of correctional health care providers that take
place every year. Prior to the conference, IDCR hosted a pre-
conference seminar and the Society for Correctional Physicians
held its annual meeting. The conference sessions featured eight
simultaneous tracks over three days, to the desperation of some
attendees, who had too many quality presentations to choose
from. Fortunately, audiotapes and handouts from are still avail-
able for sale (to obtain copies visit https://www.nrstaping.com/
ncchc/ncchc2004fall.php).
Over 200 correctional healthcare workers attended IDCR's pre-
conference seminar, which was made possible again this year
with the generous support of GlaxoSmithKline (GSK). Karl
Brown MD (Infectious Disease Supervisor at Riker's Island Jail)
provided a great number of detailed slides that illustrated the
manifestations of syphilis, gonorrhea, chlamydia, and chancroid
in correctional settings. Joseph Bick MD, (IDCR Co-chief editor
and Director of the California Medical Facility, California
Department of Corrections) spoke on infection control within the
correctional setting, illuminating a number of barriers to cleanli-
ness that impact on the transmission of infections in prisons and
jail. Annie De Groot MD (IDCR Co-chief editor, Brown
University) provided an update on HIV treatment recommenda-
tions for pregnant women. She pointed out a number of medica-
tions that are contraindicated and suggested that participants
keep up with changes in the guidelines by accessing the Health
and Human Services website on (http://hab.hrsa.gov/women-
care.htm). Neil Fisher MD (Medical Director at Martin
Correctional Institute) concluded the IDCR pre-conference sem-
inar with a discussion on new 2004 HIV medications and guide-
lines, which will be the focus of the January 2005 issue of IDCR.
IDCR board members also presented seminars during the con-
ference proper. Jody Rich MD discussed methadone mainte-
nance and harm reduction in state and federal prisons. Joe Paris
MD, PhD presided over a symposium on hepatitis C virus (HCV)
that discussed HCV screening and testing, the role of liver biop-
sy, and treatment guidelines. David Paar MD delivered a rousing
seminar on HIV treatment guidelines from his perspective as a
correctional HIV provider in the Texas Department of
Corrections.
DISCLOSURES: *Nothing to disclose
**Consultant and Speaker's Bureau: Abbott Laboratories,
Boehringer Ingelheim Pharmaceuicals, GlaxoSmithKline, Gilead
Sciences, Merck, Roche Pharmaceuticals, and Schering-Plough
^Nothing to disclose
The first annual Stephen Tabet award was given to Diane Rechtine on November 14, 2004 at the National Conference on
Correctional Healthcare in New Orleans, La. Dr. Rechtine has exhibited unending dedication to improving correctional
healthcare and has tirelessly advocated for her patients. All of us at IDCR believe that Dr. Tabet would be proud of this
wonderful clinician being recognized as the first recipient of this award. Next month, managing editor Courtney Colton will
present a spotlight on the career and accomplishments of Dr. Rechtine.
FIRST ANNUAL STEPHEN TABET AWARD PRESENTED AT NCCHC
HIGHLIGHTS OF THE 2004 ANNUAL
NCCHC MEETING IN NEW ORLEANS
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INMATE PEER EDUCATION...(continued from page 6)
Contributed by Joseph E. Paris*, PhD, MD, Annie De Groot**, MD and
Courtney Colton^
World AIDS Day
December 1
Get Involved and Make a
Difference!
14th Texas HIV/STD
Conference
December 13-17
Austin, TX
Visit: www.tdh.state.tx.us/hivstd/
conf/2004/default.htm
Conference on Retroviruses
and Opportunistic Infections
February 22 – 25, 2005
Boston, MA
Visit:
www.retroconference.org/2005
Management of HIV/AIDS in
the Correctional Setting: A
Live Satellite Videoconference
Series “The Triply Diagnosed
Patient: HIV, Mental Health &
Substance Use”
March 9, 2005
12:30-2:30 p.m. EST
Call: 518.262.4674
E-mail: ybarraj@mail.amc.edu
Visit: www.amc.edu/patient/
hiv/hivconf/index.htm
Improving the Management of
HIV Disease Regional CME
Courses
Atlanta, GA: March 11, 2005
New York, NY: March 17, 2005
Los Angeles, CA: April 16, 2005
Chicago, IL: May 2, 2005
Washington, DC: May 2005
San Francisco, CA:
May or June 2005: Registration
for this course will open soon.
Visit: www.iasusa.org/
registration/index.html.
Submit Your Articles to IDCR!
Anyone interested, please 
contact Courtney Colton at
Courtney_Colton@brown.edu
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Efficacy of Valacyclovir and Acyclovir for
Suppression of HSV Evaluated
The efficacy of valacyclovir and acyclovir on geni-
tal herpes simplex virus (HSV) shedding was
assessed in a double-blind, three-period crossover
trial involving 69 HSV infected patients. Patients
were assigned to one of three groups;  400mg oral
acyclovir twice daily, 500mg oral valacyclovir twice
daily, or placebo twice daily.  After seven weeks of
initial treatment, each participant crossed over to
the second treatment for seven weeks, and then to
the third treatment for the final seven weeks.  It
was found that both valacyclovir and acyclovir
were associated with lower HSV shedding, both in
quantity and frequency, as measured by PCR and
culture, compared to the placebo. Total suppres-
sion of HSV viral replication was not achieved in
either of the treatment groups.
Anna Wald, Rachna Gupta, Elizabeth Krantz, et al.
JID, 2004.
NATAP-www.natap.org
Michigan Prisons Get $1.2M to Test for HCV
Governor Jennifer Granholm recently signed legis-
lation giving $1.2 million for a new HCV testing and
treatment program for Michigan prisoners. This is
the state's first step in a plan to fight the spread of
HCV inside its 42 prisons.  Granholm proposed the
program earlier this year after a State Journal
report in September 2003 found up to 18,000 of
48,000 Michigan inmates harbor HCV.
NATAP-www.natap.org
Long-Term Outcome Looks Good
Data was obtained for 343 patients with chronic
HCV and then evaluated for sustained virological
response (SVR), defined as no detectable HCV-
RNA in serum at six months of treatment.  Of 343
patients treated for chronic hepatitis C, 286
patients had a SVR. Among the patients with a
SVR, the rate of decompensated liver cirrhosis and
HCC was 1.0% and 0%, respectively. The stan-
dard mortality rate was 1.4 and there was no sta-
tistically significant difference in mortality between
sustained virologic responders and the general
population, matched for age and sex.  Combination
therapy leads to higher sustained virologic
response rates than does monotherapy. In patients
who had been treated with interferon monotherapy,
the late relapse rate was 4.7%.  In patients who
were treated with both interferon and ribavirin, after
four years of follow-up, the late virologic relapse
rate was 3% and 1%, for patients treated for 24
and 48 weeks, respectively. After treatment with
pegylated interferon with or without ribavirin, after
4 years of follow-up, a late relapse rate of 0.8%
was reported.
Gut. October, 2004. 
NATAP-www.natap.org
Solid-Organ Transplant in HIV-Infected
Patients
Traditionally, HIV-infected patients are often not
considered for solid-organ transplants, including
liver and kidney. However, improvements in anti-
retroviral therapy, opportunistic infection prophy-
laxis, and treatment to prevent rejection have
made solid-organ transplant a possibility for HIV-
infected patients. In one study, 26 and 19 patients
received kidney and liver transplants, respectively.
At a median follow-up of 314 days, two of the 26
patients who received kidney transplants died,
while four of 19 patients who received liver trans-
plants died. Death from opportunistic infections
occurred in one of the kidney recipients and one of
the liver recipients.  At follow-up CD4+ cell counts
we e maintained and HIV RNA levels remained
largely suppressed. This study indicates that in
carefully selected patients, baseline immunologic
and virologic values can be maintained, and oppor-
tu istic infection complications are often infre-
quent.
www.iasusa.org
NATAP-www.natap.org
HIV/AIDS in Women on the Rise
In 1992, women accounted for 14% of all AIDS
cases in the United States.  However, by 1999,
women accounted for more than 20% of all AIDS
ca es. The epidemic has increased principally in
African American and Hispanic women, with these
two groups accounting for 81% of all AIDS cases
reported to date among United States women.
African American women and Hispanic women
account for 67% and 14% of all AIDS cases in
women, respectively.  Of women living with AIDS,
the two main reported transmission routes for HIV
infection are heterosexual exposure (38%) or
i jection drug use (25%). Additionally, women
aged 35-44 years were most likely to have con-
tracted HIV through injection drug use, while
women aged 20-24 were most likely to have con-
tracted HIV through heterosexual exposure. States
with the highest prevalence of AIDS cases in
women include Florida, Georgia, South Carolina,
Maryland, Delaware, New Jersey, New York, and
Connecticut.
NATAP-www.natap.org
HCV Clearance Examined in Injection Drug
Users (IDUs)
A retrospective cohort of IDUs with HCV infection
was established to examine spontaneous viral
clearance, defined as two consecutive negative
HCV RNA test results after infection.  Estimates of
viral clearance at six, 12, and 24 months were
27%, 42%, and 45%, respectively, for IDUs who
experienced HCV antibody seroconversion
between 1992-1996, compared with 19%, 34%,
and 34%, respectively, for IDUs who experienced
seroconversion between 1997-2002.  Most cases
of viral clearance occurred within the initial 12
months after the estimated time of infection, but
spontaneous viral clearance did extend to as late
as 24 months.
Marianne Jauncey, Joanne Micallef, Stuart
Gilmour, et al.  JID, October 2004.
NATAP-www.natap.org
IN THE NEWS
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RESOURCES
HIV Resistance Testing 
Fact Sheets: 
www.aids.org
Project Inform: 
www.projinf.org
www.aegis.com
SELF-ASSESSMENT TEST FOR CONTINUING MEDICAL EDUCATION CREDIT
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through May 31, 2005. 
The estimated time for completion of this activity is one hour and there is no fee for participation.
1. There are currently three different types of assays commercial-
ly available to evaluate for HIV resistance: phenotype, genotype,
and inhibitor resistance tests. True or False?
a. True
b. False
2. Regarding genotypic resistance testing, which of the following
statements are true?
a. The viral amino acid sequence that differs from wild type 
is reported.
b. An interpretation that assesses the impact of a set of 
mutations is provided.
c. Testing can be reliably conducted when the HIV viral load 
is below 250.
d. A and C
e. A and B
3. Resistance testing is recommended in the following situations:
a. Patients with acute HIV infection
b. Males over the age of 60
c. Patients with chronic HIV infection who are failing anti
retroviral therapy 
d. A and C
4. Which of the following are true?
a. HCV accelerates the progression of HIV disease.
b. HIV accelerates the progression of HCV disease.
c. Those who are coinfected with HIV and HCV are less 
likely to respond to interferon and ribavirin than those who 
are monoinfected with HCV.
d. Ribavirin should not be used in those who are infected 
with HIV due to the potential for toxicity.
e. B and C
f.  A and B
6. Genotypic resistance testing is more costly than phenotypic
resistance testing. True or False?
a. True
b. False
7. Failure to identify resistance mutations during HIV genotyping
ensures that mutations are not present: True or False?
a. True
b. False
BROWN MEDICAL SCHOOL •  OFFICE OF CONTINUING MEDICAL EDUCATION •  BOX G-A2  •  PROVIDENCE, RI 02912
The Brown Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME)to provide continuing medical 
education activities for physicians.  
The use of the Brown Medical School name implies review of the educational format and material only. The opinions, recommendations 
and editorial positions expressed by those whose input is included in this bulletin are their own. They do not represent or speak for the 
Brown Medical School.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660 or 
register online at www.IDCRonline.org. Be sure to print clearly so that we have the correct information for you.
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IDCR EVALUATION
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1      
In the News 5  4  3  2  1   5  4  3  2  1
Save the 
Dates 5  4  3  2  1   5  4  3  2  1
2. Do you feel that IDCR helps you in your work?
Why or why not?
3. What future topics should IDCR address?
4. How can IDCR be made more useful to you?
5. Do you have specific comments on this issue?
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